Cargando…

Effects of intravesical BCG maintenance therapy duration on recurrence rate in high-risk non-muscle invasive bladder cancer (NMIBC): Systematic review and network meta-analysis according to EAU COVID-19 recommendations

PURPOSE: During the coronavirus disease 2019 (COVID-19) pandemic, the European Association of Urology (EAU) recommended that courses of intravesical bacillus Calmette-Guérin (BCG) therapy lasting more than 1 year could be safely terminated for patients with high-risk non-muscle-invasive bladder canc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moon, Young Joon, Cho, Kang Su, Jeong, Jae Yong, Chung, Doo Yong, Kang, Dong Hyuk, Jung, Hae Do, Lee, Joo Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455878/ https://www.ncbi.nlm.nih.gov/pubmed/36074771 http://dx.doi.org/10.1371/journal.pone.0273733

Ejemplares similares

Effect of neoadjuvant chemotherapy on overall survival of patients with T2-4aN0M0 bladder cancer: A systematic review and meta-analysis according to EAU COVID-19 recommendation
por: Kang, Dong Hyuk, et al.
Publicado: (2022)

Surveillance versus Adjuvant Treatment with Chemotherapy or Radiotherapy for Stage I Seminoma: A Systematic Review and Meta-Analysis According to EAU COVID-19 Recommendations
por: Kang, Dong Hyuk, et al.
Publicado: (2022)

Intravesical ICIs to reduce toxicity in NMIBC
por: Masone, Maria Chiara
Publicado: (2022)

Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis
por: Del Giudice, Francesco, et al.
Publicado: (2022)

Treatment efficacy and tolerability of intravesical Bacillus Calmette-Guerin (BCG) - RIVM strain: induction and maintenance protocol in high grade and recurrent low grade non-muscle invasive bladder cancer (NMIBC)
por: Farah, Naim B, et al.
Publicado: (2014)

Immune responses against SARS-CoV-2 wildtype in unvaccinated patients with high-risk NMIBC undergoing intravesical BCG therapy
por: Pichler, R., et al.
Publicado: (2023)

The use of intravesical BCG in urothelial carcinoma of the bladder
por: Alhunaidi, Omar, et al.
Publicado: (2019)

Systemic BCG‐osis following intravesical BCG instillation for bladder carcinoma
por: Liaw, Frank, et al.
Publicado: (2017)

BCG instillation versus radical cystectomy for high-risk NMIBC with squamous/glandular histologic variants
por: Suh, Jungyo, et al.
Publicado: (2019)

Disseminated BCG: Complications of Intravesical Bladder Cancer Treatment
por: To, Uyen, et al.
Publicado: (2014)

Bladder Sparing Therapy for BCG Failures – I – Intravesical Immunotherapy
por: Messing, Edward M.
Publicado: (2017)

Mycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer
por: Seegobin, Karan, et al.
Publicado: (2017)

Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer
por: Buffen, Kathrin, et al.
Publicado: (2014)

Asymptomatic renal BCG granulomatosis: An unusual complication of intravesical BCG therapy for carcinoma urinary bladder
por: Bhat, Suresh, et al.
Publicado: (2015)

Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non–muscle‐invasive bladder cancer (NMIBC): A cohort analysis
por: Jobczyk, Mateusz, et al.
Publicado: (2020)

Outcomes of BCG Induction in High-Risk Non-Muscle-Invasive Bladder Cancer Patients (NMIBC): A Retrospective Cohort Study
por: Pirzada, Muhammad T, et al.
Publicado: (2017)

Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
por: Saban, Marcia R, et al.
Publicado: (2007)

Mycobacterial Osteomyelitis of the Spine Following Intravesical BCG Therapy for Bladder Cancer
por: Mackel, Charles E, et al.
Publicado: (2016)

Role of Intravesical BCG as a Therapeutic Vaccine for Treatment of Bladder Carcinoma
por: Doroud, Delaram, et al.
Publicado: (2022)

Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer
por: Lukacs, S., et al.
Publicado: (2013)

Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG
Publicado: (2015)

Intravesical ALT-803 for BCG-unresponsive Bladder Cancer – A Case Report
por: Huang, Jeffrey, et al.
Publicado: (2017)

Multisystemic BCGitis: A rare complication of intravesical BCG immunotherapy for bladder cancer
por: Vilares, Ana T., et al.
Publicado: (2022)

Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
por: Cooper, Owen Alan Edwards, et al.
Publicado: (2023)

Pott's disease post intravesical BCG
por: Jain, Anika
Publicado: (2023)

Pott’s Disease Caused by Mycobacterium bovis Following Intravesical BCG Therapy for Bladder Cancer
por: Jones, Zachary, et al.
Publicado: (2017)

Mycotic aortic aneurysms post-Intravesical BCG treatment for early-stage bladder carcinoma
por: Wadhwani, Aman, et al.
Publicado: (2018)

Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients
por: de Jong, Joep J., et al.
Publicado: (2018)

Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors
por: Moreo, Eduardo, et al.
Publicado: (2022)

Haemophagocytic lymphohistiocytosis after intravesical BCG administration for bladder cancer presenting with multiorgan failure
por: Liatsos, G. D., et al.
Publicado: (2023)

Multi-country clinical practice patterns, including use of biomarkers, among physicians’ treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)
por: Broughton, Edward I., et al.
Publicado: (2022)

Editorial: New frontiers in “bladder sparing” treatments for high risk NMIBC
por: Hurle, Rodolfo, et al.
Publicado: (2023)

Phase I study of patients with non-muscle invasive bladder cancer (NMIBC) treated with vesigenurtacel-L (HS-410) after Bacillus Calmette-Guérin (BCG)
por: Steinberg, Gary, et al.
Publicado: (2015)

Renal Tuberculosis Following Intravesical Bacillus Calmette–Guérin (BCG) Immunotherapy for the Treatment of Bladder Cancer
por: Bajramovic, Senad, et al.
Publicado: (2020)

Correction to: Mycotic aortic aneurysms post-Intravesical BCG treatment for early-stage bladder carcinoma
por: Wadhwani, Aman, et al.
Publicado: (2019)

SAT-666 Possible Amelioration of Diabetic State After Intravesical BCG Instillations for Bladder Cancer
por: Havranova, Jana, et al.
Publicado: (2020)

Case Report with Systematic Literature Review on Vascular Complications of BCG Intravesical Therapy for Bladder Cancer
por: King, Brianna, et al.
Publicado: (2022)

The bladder microbiome of NMIBC and MIBC patients revealed by 2bRAD-M
por: Sun, Jian-Xuan, et al.
Publicado: (2023)

Weekly intravesical bacillus Calmette-Guerin (BCG) alternating with epirubicin in Ta and T1 urothelial bladder cancer: An approach to decrease BCG toxicity
por: Ali-El-Dein, Bedeir, et al.
Publicado: (2013)

Evaluating the Effectiveness of Intravesical Instillation of BCG by Modified Maintenance Method in Patients With High-Risk Ta and T1 Bladder Cancer: A Randomized Clinical Trial
por: Shakhssalim, Nasser, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ab7agtlcr0ued32gioeqs23eq3